Search Results - "Agunwamba, Blessing"

Nivolumab plus Ipilimumab in Advanced Melanoma by WOLCHOK, Jedd D, KLUGER, Harriet, BURKE, Matthew M, CALDWELL, Anne, KRONENBERG, Stephanie A, AGUNWAMBA, Blessing U, XIAOLING ZHANG, LOWY, Israel, INZUNZA, Hector David, FEELY, William, HORAK, Christine E, QUAN HONG, CALLAHAN, Margaret K, KORMAN, Alan J, WIGGINTON, Jon M, GUPTA, Ashok, SZNOL, Mario, POSTOW, Michael A, RIZVI, Naiyer A, LESOKHIN, Alexander M, SEGAL, Neil H, ARIYAN, Charlotte E, GORDON, Ruth-Ann, REED, Kathleen

Get full text

Nivolumab plus Ipilimumab in Advanced Melanoma by Wolchok, Jedd D, Kluger, Harriet, Callahan, Margaret K, Postow, Michael A, Rizvi, Naiyer A, Lesokhin, Alexander M, Segal, Neil H, Ariyan, Charlotte E, Gordon, Ruth-Ann, Reed, Kathleen, Burke, Matthew M, Caldwell, Anne, Kronenberg, Stephanie A, Agunwamba, Blessing U, Zhang, Xiaoling, Lowy, Israel, Inzunza, Hector David, Feely, William, Horak, Christine E, Hong, Quan, Korman, Alan J, Wigginton, Jon M, Gupta, Ashok, Sznol, Mario

“…A combination of antibodies to two T-cell checkpoints, CTLA-4 and PD-1, produced tumor responses in 40% of patients in a phase 1 study. Elevated lipase levels…”
Get full text

The CPEB protein Orb2 has multiple functions during spermatogenesis in Drosophila melanogaster by Xu, Shuwa, Hafer, Nathaniel, Agunwamba, Blessing, Schedl, Paul

“…Cytoplasmic Polyadenylation Element Binding (CPEB) proteins are translational regulators that can either activate or repress translation depending on the…”
Get full text

Nivolumab and Ipilimumab in Advanced Melanoma by Ryu, Hyewon, Lee, Hyo Jin, Alegre-del Rey, Emilio J, de la Nogal Fernández, Blanca, Briceño-Casado, Pilar, Wolchok, Jedd D, Rollin, Linda, Larkin, James

“…To the Editor: In reporting the 3-year overall survival outcomes of the CheckMate 067 trial, Wolchok et al. (Oct. 5 issue) 1 indicate that nivolumab combined…”
Get full text

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) by Sznol, Mario, Kluger, Harriet M., Callahan, Margaret K., Postow, Michael Andrew, Gordon, Ruth Ann, Segal, Neil Howard, Rizvi, Naiyer A., Lesokhin, Alexander M., Atkins, Michael B., Kirkwood, John M., Burke, Matthew M., Ralabate, Amanda L., Rivera, Angel L., Kronenberg, Stephanie Anne, Agunwamba, Blessing, Feely, William, Hong, Quan, Krishnan, Suba, Gupta, Ashok Kumar, Wolchok, Jedd D.

“…Abstract only LBA9003^ Background: We report updated survival and clinical activity in initially enrolled cohorts and activity by BRAF MT status in a phase I…”
Get full text

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) by Sznol, Mario, Kluger, Harriet M., Callahan, Margaret K., Postow, Michael Andrew, Gordon, Ruth Ann, Segal, Neil Howard, Rizvi, Naiyer A., Lesokhin, Alexander M., Atkins, Michael B., Kirkwood, John M., Burke, Matthew M., Ralabate, Amanda L., Rivera, Angel L., Kronenberg, Stephanie Anne, Agunwamba, Blessing, Feely, William, Hong, Quan, Krishnan, Suba, Gupta, Ashok Kumar, Wolchok, Jedd D.

“…Abstract only…”
Get full text

Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients by Wolchok, Jedd D., Kluger, Harriet, Callahan, Margaret K., Postow, Michael A., Rizvi, Naiyer A., Lesokhin, Alexander M., Segal, Neil H., Ariyan, Charlotte E., Gordon, Ruth-Ann, Reed, Kathleen, Burke, Matthew M., Caldwell, Anne, Kronenberg, Stephanie A., Agunwamba, Blessing U., Zhang, Xiaoling, Lowy, Israel, Inzunza, Hector David, Feely, William, Horak, Christine E., Hong, Quan, Korman, Alan J., Wigginton, Jon M., Gupta, Ashok, Sznol, Mario

Get full text

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL) by Wolchok, Jedd D., Kluger, Harriet M., Callahan, Margaret K., Postow, Michael Andrew, Gordon, Ruth Ann, Segal, Neil Howard, Rizvi, Naiyer A., Lesokhin, Alexander M., Reed, Kathleen, Burke, Matthew M., Caldwell, Anne, Kronenberg, Stephanie Anne, Agunwamba, Blessing, Feely, William, Hong, Quan, Horak, Christine E., Korman, Alan J., Wigginton, Jon M., Gupta, Ashok Kumar, Sznol, Mario

“…Abstract only 9012^ Background: CTLA-4 and PD-1 are critical immune checkpoint receptors. In MEL pts, ipilimumab (anti-CTLA-4) prolonged survival in two phase…”
Get full text